Compare Regeneron Pharmaceuticals Inc (REGN) vs Suncor Energy Inc. (SU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Suncor Energy Inc. — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B), while Suncor Energy Inc. trades at $69.27 (market cap $79.39B). The key difference: Regeneron Pharmaceuticals Inc and Suncor Energy Inc. are close in size by market cap, and Suncor Energy Inc. pays the higher dividend (2.55%). Which is the better fit depends on your goals.
| REGN | SU | |
|---|---|---|
Market Cap | $83.43B | $79.39B |
Sector | Health | Energy |
52-Week High | $852.03 | $69.73 |
52-Week Low | $555.51 | $38.17 |
Enterprise Value | $78.14B | $86.13B |
Dividend Yield | 0.46% | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Suncor Energy (SU) trades at $67.89, up 0.83% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 12.54 and net income margin of 14.7%, supported by Q2 2026 earnings beating estimates. Recent news highlights leadership transition to Peter Zebedee as CEO in 2027 and a dividend declaration of $0.60 per share payable September 25, 2026.
Outlook remains positive due to robust cash flow and buyback increases, but risks include commodity price volatility and operational challenges from weather events. Analyst consensus is strongly bullish with 74% buy ratings, indicating confidence in sustained performance amid energy market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
